Preclinical Evidence of Alzheimer Changes: Convergent Cerebrospinal Fluid Biomarker and Fluorodeoxyglucose Positron Emission Tomography Findings

BACKGROUND: Alterations in cerebrospinal fluid (CSF) tau and β–amyloid peptide 1–42 (Aβ(42)) levels and rates of cerebral glucose (CMRglu) on fluorodeoxyglucose positron emission tomography (FDG PET) occur years before clinical symptoms of Alzheimer’s disease (AD) become manifest, but their relation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Petrie, Eric C., Cross, Donna J., Galasko, Douglas, Schellenberg, Gerard D., Raskind, Murray A., Peskind, Elaine R., Minoshima, Satoshi
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2718788/
https://ncbi.nlm.nih.gov/pubmed/19433663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2009.59
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados